相关临床试验
581
72 进行中
药物批准
5
批准总数
监管机构
1
监管机构数
成立时间
1970
进行中（未招募）
45
7.8%
已完成
281
48.4%
Enrolling By Invitation
2
0.3%
尚未招募
25
4.3%
招募中
71
12.2%
暂停
3
0.5%
终止
28
4.8%
Unknown
120
20.6%
撤回
6
1.0%
- DelveInsight's 2025 pipeline report reveals over 165 companies are developing 170+ investigational therapies for triple-negative breast cancer (TNBC), spanning from preclinical to Phase III trials. - Key emerging therapies include trilaciclib (G1 Therapeutics), olaparib (AstraZeneca), and patritumab deruxtecan (Daiichi Sankyo/Merck), with several receiving breakthrough therapy designations and showing promising clinical results. - Recent clinical milestones include Akeso's ivonescimab receiving breakthrough therapy designation from China's NMPA and Kazia Therapeutics reporting an immune-complete response in a stage IV TNBC patient treated with paxalisib combination therapy. - The TNBC therapeutics market is expected to experience substantial growth driven by rising incidence rates, improved diagnostics, increased awareness, and the anticipated introduction of novel treatment options.
- Hengrui's CARES-009 trial demonstrated that perioperative camrelizumab plus rivoceranib more than doubled event-free survival compared to surgery alone in resectable hepatocellular carcinoma patients. - The combination achieved a major pathological response rate of 35.1% versus 7.5% with surgery alone, with manageable safety profile and only 8% discontinuation rate. - These results represent a potential paradigm shift in HCC treatment, as no standard perioperative therapies currently exist for this cancer with high recurrence rates. - The findings could establish perioperative PD-1 plus VEGFR inhibition as a new global standard of care, particularly significant given China's dominance in global HCC cases.
- DelveInsight's 2025 report reveals over 165 companies are developing 170+ pipeline therapies for triple-negative breast cancer, driven by rising disease prevalence and growing research investments. - Recent clinical milestones include Cardiff Oncology's positive Phase 1b data for onvansertib plus paclitaxel, Akeso's breakthrough therapy designation for ivonescimab combination, and multiple Phase III studies initiated by AstraZeneca and others. - Leading pipeline candidates include trilaciclib (G1 Therapeutics), olaparib (AstraZeneca), and patritumab deruxtecan (Daiichi Sankyo/Merck), representing diverse therapeutic approaches from CDK4/6 inhibitors to antibody-drug conjugates. - The TNBC therapeutics market is expected to undergo substantial growth due to improved diagnostics, increased awareness, higher healthcare spending, and anticipated launches of innovative treatments.
- DelveInsight's 2025 pipeline analysis reveals 25+ companies developing 28+ therapies for gastrointestinal stromal tumors, indicating strong industry investment in this rare cancer space. - Merck Sharp & Dohme initiated a belzutifan monotherapy study in August 2025 for advanced wild-type GIST and other rare tumors, with objective response rate as the primary endpoint. - Key pipeline candidates include famitinib in Phase III development by Jiangsu Hengrui Medicine and novel approaches like Daiichi Sankyo's first-in-class GPR20-targeting ADC DS-6157. - Theseus Pharmaceuticals' THE-630 represents a promising pan-variant KIT inhibitor designed to overcome resistance mutations that limit current GIST therapies.
- DelveInsight's 2025 pipeline analysis reveals over 20 companies are actively developing 20+ novel therapies for ankylosing spondylitis treatment across various clinical phases. - UCB's BIMZELX demonstrated long-term inflammation control in three-year Phase 3 data, while becoming the first dual IL-17A/IL-17F inhibitor approved in Canada for ankylosing spondylitis. - Multiple promising candidates including sonelokimab, NEU-111, and secukinumab are advancing through clinical trials, targeting different pathways to address unmet medical needs. - The pipeline encompasses diverse therapeutic approaches including monoclonal antibodies, small molecules, and nanobodies administered through oral, subcutaneous, and intravenous routes.
- Jiangsu Hengrui Medicine secured inclusion of two products on China's proposed breakthrough therapy list, highlighting their potential to address unmet medical needs in gastric cancer treatment. - The company received US FDA orphan drug designation for trastuzumab for injection, providing development incentives including tax credits and market exclusivity for this gastric cancer therapy. - Hengrui obtained clinical trial approval for three oncology drugs, enabling advancement of its cancer treatment research and potential commercialization of innovative therapies. - The pharmaceutical company partnered with GlaxoSmithKline to develop up to 12 innovative medicines across respiratory, immunology, inflammation, and oncology therapeutic areas.
- DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment. - Merck's KEYNOTE-811 Phase III trial achieved its dual primary endpoint of overall survival in July 2024, evaluating Keytruda combination therapy for first-line treatment. - ENHERTU received US approval in April 2024 as the first tumor-agnostic HER2-targeted therapy for metastatic HER2-positive solid tumors. - Leading pipeline candidates include SHR-A1811 from Jiangsu HengRui Medicine, Cinrebafusp alfa from Pieris Pharmaceuticals, and BI-1607 from BioInvent International.
- A multicenter retrospective study of 108 patients demonstrated that tislelizumab, with or without tyrosine kinase inhibitors, significantly extended recurrence-free survival in high-risk hepatocellular carcinoma patients after curative resection. - Patients receiving adjuvant therapy for at least 6 months showed significantly longer recurrence-free survival compared to those treated for less than 6 months, with RFS rates of 89.8%, 71.3%, and 59.3% at 6, 12, and 24 months respectively. - Combination therapy with TKIs did not provide additional survival benefit over tislelizumab monotherapy but resulted in significantly higher rates of grade 3 or higher treatment-related adverse events (38.5% vs 18.6%). - The findings suggest tislelizumab monotherapy may be the optimal adjuvant approach for preventing HCC recurrence, balancing efficacy with acceptable toxicity profiles.
- The global thrombocytopenia clinical trials landscape is expanding rapidly with over 25 pharmaceutical companies developing 25+ treatment therapies, according to recent market analysis. - Key industry players including GSK, Novartis, Amgen, and Sanofi are leading clinical development efforts, with several promising candidates in late-stage trials showing efficacy in reducing thrombocytopenia events. - Recent advances include Takeda's TAK-755 demonstrating 60% reduction in thrombocytopenia events compared to standard of care, and HUTCHMED completing enrollment for its pivotal Phase III ESLIM-01 trial of sovleplenib for immune thrombocytopenia.
- Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report. - Leading companies in hyperuricemia drug development include LG Chem, Shanton Pharma, InventisBio, Jiangsu HengRui Medicine, and Selecta Biosciences, with treatments spanning oral, intravenous, and subcutaneous administration routes. - A significant development occurred in December 2024 when Atom Therapeutics partnered with China Medical System Holdings to commercialize lingdolinurad (ABP-671), a novel URAT1 inhibitor for chronic gout and hyperuricemia in China.
